Ollin Biosciences has successfully closed an oversubscribed Series B financing round, securing $330 million to advance its innovative treatments for vision loss. The capital will primarily fund global Phase 3 trials for its lead candidate, OLN324, a promising therapy for retinal vascular diseases. This significant investment propels the company forward in its mission to address major causes of blindness in a multi-billion dollar market.
Significant Investor Confidence
The financing was co-led by new investor TCGX and founding investor ARCH Venture Partners, demonstrating robust support from both new and existing backers. A distinguished syndicate of healthcare-focused institutional investors, including a16z Bio+Health and Blackstone, also participated in the round. This broad coalition of premier investors underscores strong confidence in Ollin's scientific approach and the commercial potential of its pipeline.
Advancing a Promising Retinal Therapy
Proceeds are earmarked for the global Phase 3 development of OLN324, targeting diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). Beyond its lead program, the company also plans to advance another drug candidate into clinical development within the year. This strategic allocation of funds will accelerate Ollin's efforts to bring next-generation therapies to patients suffering from serious eye conditions.
OLN324 is a next-generation bispecific antibody engineered to target both VEGF and Ang2, two key drivers of retinal disease. The drug was designed with substantially higher Ang2 potency compared to existing treatments, aiming to improve vascular stability and reduce inflammation. Its unique molecular design positions it as a potential best-in-class treatment for conditions that cause significant vision impairment.
Positive Clinical Trial Results
In a recent head-to-head clinical study, OLN324 demonstrated superior performance against the current therapy, faricimab. The JADE trial showed that Ollin's drug achieved meaningfully faster and greater improvements in retinal anatomy for patients. Furthermore, the candidate showed numerically greater vision gains, providing a strong foundation for its advancement into late-stage development.
Ollin has already engaged with key regulatory bodies, successfully completing an End-of-Phase 2 meeting with the U.S. Food and Drug Administration. The company has also received positive scientific advice from the European Medicines Agency regarding its planned Phase 3 program. These constructive interactions pave the way for the initiation of global registrational trials in the second half of 2026.
Strategic Partnership and Market Opportunity
The development of OLN324, also known as IBI324, is a collaborative effort with its partner Innovent Biologics, which originally discovered the molecule. This strategic partnership will be instrumental in conducting the global Phase 3 trials, extending the program's reach to include China and South Korea. The collaboration leverages the strengths of both companies to accelerate the drug's path to patients worldwide.
The company is targeting the $15 billion global retina market, where there remains a significant need for more effective and durable treatments. OLN324's differentiated clinical profile suggests it could offer a new standard of care for physicians and their patients. This financing provides the necessary resources to pursue this substantial commercial opportunity and challenge the status quo in ophthalmology.
With $330 million in new funding, Ollin Biosciences is strongly positioned to advance its lead candidate through pivotal late-stage clinical trials. The company's promising clinical data and strategic partnerships create a clear path toward addressing unmet needs in retinal vascular disease. This development marks a significant step in Ollin's journey to deliver a potentially transformative therapy to patients globally.